0HF3 Stock Overview Cencora, Inc. sources and distributes pharmaceutical products in the United States and internationally. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Cencora, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Cencora Historical stock prices Current Share Price US$226.01 52 Week High US$254.02 52 Week Low US$204.96 Beta 0.46 1 Month Change -10.15% 3 Month Change 0.84% 1 Year Change 10.82% 3 Year Change 68.88% 5 Year Change 170.51% Change since IPO 114.27%
Recent News & Updates Cencora Launches Accelerate Pharmacy Solutions to Enhance Support for Hospital and Health System Customers Dec 06
Executive Chairman recently sold US$12m worth of stock Nov 27
Fourth quarter dividend increased to US$0.55 Nov 08
Cencora, Inc. Declares Quarterly Dividend, Payable on November 29, 2024 Nov 07
Full year 2024 earnings released: EPS: US$7.60 (vs US$8.62 in FY 2023) Nov 07 Cencora, Inc. (NYSE:COR) entered into a definitive agreement to acquire 85% stake in Retina Consultants of America from Webster Capital IV, L.P., fund managed by Webster Equity Partners, L.P. for $5.1 billion. Nov 07
See more updates Cencora Launches Accelerate Pharmacy Solutions to Enhance Support for Hospital and Health System Customers Dec 06
Executive Chairman recently sold US$12m worth of stock Nov 27
Fourth quarter dividend increased to US$0.55 Nov 08
Cencora, Inc. Declares Quarterly Dividend, Payable on November 29, 2024 Nov 07
Full year 2024 earnings released: EPS: US$7.60 (vs US$8.62 in FY 2023) Nov 07 Cencora, Inc. (NYSE:COR) entered into a definitive agreement to acquire 85% stake in Retina Consultants of America from Webster Capital IV, L.P., fund managed by Webster Equity Partners, L.P. for $5.1 billion. Nov 07
Cencora, Inc. (NYSE:COR) entered into a definitive agreement to acquire 85% stake in Retina Consultants of America from Webster Capital IV, L.P., fund managed by Webster Equity Partners, L.P. for $5.1 billion. Nov 06
Cencora, Inc. Announces Management Appointments Nov 05
Cencora, Inc. to Report Q4, 2024 Results on Nov 06, 2024 Oct 01
Cencora, Inc. Elects Frank Clyburn as New Independent Director, Effective October 1, 2024 Aug 15
Third quarter dividend of US$0.51 announced Aug 02
Third quarter 2024 earnings released: EPS: US$2.44 (vs US$2.37 in 3Q 2023) Aug 01
Cencora, Inc. Declares Quarterly Cash Dividend, Payable on August 26, 2024 Jul 31
Cencora, Inc. to Report Q3, 2024 Results on Jul 31, 2024 Jul 06
Second quarter dividend of US$0.51 announced May 03
Cencora, Inc. Declares Quarterly Cash Dividend on Common Share, Payable on May 24, 2024 May 03
Second quarter 2024 earnings released: EPS: US$2.11 (vs US$2.15 in 2Q 2023) May 01
Cencora, Inc. (NYSE:COR) announces an Equity Buyback for $2,000 million worth of its shares. May 01
Cencora, Inc. to Report Q2, 2024 Results on May 01, 2024 Apr 06
Cencora, Inc. Reaffirms Guidance for Year 2024 Mar 15
Cencora, Inc. Announces CEO Changes, Effective October 1, 2024 Mar 13 Cencora, Inc. Announces CEO Changes, Effective October 1, 2024
Cencora’s FormularyDecisions Launches Payer Resource for Cell and Gene Therapy Products Feb 08
First quarter dividend of US$0.51 announced Feb 02
First quarter 2024 earnings released: EPS: US$3.01 (vs US$2.35 in 1Q 2023) Feb 01
Cencora, Inc. Declares Quarterly Cash Dividend on Common Share, Payable on February 26, 2024 Jan 31
Cencora, Inc., Annual General Meeting, Mar 12, 2024 Jan 18 Cencora, Inc., Annual General Meeting, Mar 12, 2024
Cencora, Inc. to Report Q1, 2024 Results on Jan 31, 2024 Jan 05
Chairman recently sold US$8.7m worth of stock Dec 17
Now 20% undervalued Nov 30
Insider recently sold US$2.0m worth of stock Nov 18
Now 21% undervalued Nov 15
Cencora, Inc. Declares Quarterly Dividend, Payable November 27, 2023 Nov 03
Full year 2023 earnings released: EPS: US$8.62 (vs US$8.15 in FY 2022) Nov 02
Now 20% undervalued Oct 27
Now 20% undervalued after recent price drop Oct 11
Cencora, Inc. to Report Q4, 2023 Results on Nov 02, 2023 Oct 05 Amerisourcebergen Corporation Elects Werner Baumann and Lauren Tyler to Its Board of Directors Aug 17
Now 20% undervalued Aug 15
AmerisourceBergen Corporation Declares Quarterly Cash Dividend, Payable on August 28, 2023 Aug 03
Third quarter 2023 earnings released: EPS: US$2.37 (vs US$1.95 in 3Q 2022) Aug 03
AmerisourceBergen Corporation to Report Q3, 2023 Results on Aug 02, 2023 Jun 30
TPG Inc. (NasdaqGS:TPG), AmerisourceBergen Corporation (NYSE:ABC) and the management team of OneOncology, Inc. acquired OneOncology, LLC from General Atlantic Service Company, L.P. and others. Jun 10
Executive VP & Chief Legal Officer recently sold US$731k worth of stock May 21
Second quarter 2023 earnings released: EPS: US$2.15 (vs US$2.62 in 2Q 2022) May 03
Now 21% undervalued Apr 26
Insider recently sold US$301k worth of stock Mar 05
Senior VP recently sold US$890k worth of stock Feb 12
First quarter 2023 earnings released: EPS: US$2.35 (vs US$2.15 in 1Q 2022) Feb 02 An unknown buyer acquired Brazil specialty business from AmerisourceBergen Corporation (NYSE:ABC). AmerisourceBergen Corporation, Annual General Meeting, Mar 09, 2023
AmerisourceBergen Corporation, Annual General Meeting, Mar 09, 2023 Jan 27
AmerisourceBergen Corporation to Report Q1, 2023 Results on Feb 01, 2023 Jan 04
Insider recently sold US$137k worth of stock Dec 22
Executive VP & Chief Strategy Officer recently sold US$501k worth of stock Dec 13
Full year 2022 earnings released: EPS: US$8.15 (vs US$7.48 in FY 2021) Nov 24
AmerisourceBergen Corporation Elects Redonda Miller to Its Board of Directors, Effective January 1, 2023 Nov 17 AmerisourceBergen Corporation has completed a Follow-on Equity Offering in the amount of $1.546 billion. Nov 09
Full year 2022 earnings released: EPS: US$8.15 (vs US$7.48 in FY 2021) Nov 04 AmerisourceBergen Corporation Appoints Robert P. Mauch as Executive Vice President and Chief Operating Officer
AmerisourceBergen Corporation to Report Q4, 2022 Results on Nov 03, 2022 Sep 29
AmerisourceBergen Elects Lorence H. Kim, M.D., to Its Board of Directors Sep 28
AmerisourceBergen Corporation (NYSE:ABC) agreed to acquire Pharmalex Holding Gmbh from AUCTUS Capital Partners AG for €1.3 billion. Sep 14
AmerisourceBergen Corporation (NYSE:ABC) agreed to acquire Pharmalex Holding Gmbh for €1.28 billion. Sep 13
Third quarter 2022 earnings released: EPS: US$1.95 (vs US$1.42 in 3Q 2021) Aug 04 AmerisourceBergen Corporation Reports Goodwill Impairment for the Three Months Ended June 30, 2022
AmerisourceBergen to Launch Digital Therapeutics Platform to Facilitate Access to Innovative Products Jul 28
AmerisourceBergen Corporation to Report Q3, 2022 Results on Aug 03, 2022 Jun 30
AmerisourceBergen Corporation (NYSE:ABC) announces an Equity Buyback for $1,000 million worth of its shares. Jun 03
AmerisourceBergen Launches Clinical Trial Navigator to Bolster Equitable and Accessible Community-Based Research Opportunities Nationwide May 24
Senior VP recently sold US$783k worth of stock May 14
An unknown buyer acquired 2.9% stake in AmerisourceBergen Corporation (NYSE:ABC) from Walgreens Boots Alliance, Inc. (NasdaqGS:WBA) for $900 million. May 13
Second quarter 2022 earnings released: EPS: US$2.62 (vs US$2.12 in 2Q 2021) May 05
Amerisourcebergen Corporation Corporation Declares Quarterly Cash Dividend, Payable on May 31, 2022 May 05
Insufficient new directors Apr 27
AmerisourceBergen Launches $150 Million Venture Capital Fund Apr 07
AmerisourceBergen Corporation to Report Q2, 2022 Results on May 04, 2022 Mar 29
Insider recently sold US$1.0m worth of stock Mar 17
AmerisourceBergen, Cardinal Health and McKesson Approve Opioid Settlement Agreement Feb 26
First quarter 2022 earnings: Revenues and EPS in line with analyst expectations Feb 04
AmerisourceBergen Corporation Declares a Quarterly Cash Dividend, Payable on February 28, 2022 Feb 03 Shareholder Returns 0HF3 GB Healthcare GB Market 7D -1.2% 0.08% 0.8% 1Y 10.8% -24.8% 2.7%
See full shareholder returns
Return vs Market: 0HF3 exceeded the UK Market which returned 2.7% over the past year.
Price Volatility Is 0HF3's price volatile compared to industry and market? 0HF3 volatility 0HF3 Average Weekly Movement 2.8% Healthcare Industry Average Movement 4.6% Market Average Movement 4.7% 10% most volatile stocks in GB Market 10.4% 10% least volatile stocks in GB Market 2.6%
Stable Share Price: 0HF3 has not had significant price volatility in the past 3 months compared to the UK market.
Volatility Over Time: 0HF3's weekly volatility (3%) has been stable over the past year.
About the Company Cencora, Inc. sources and distributes pharmaceutical products in the United States and internationally. The company’s U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and other services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.
Show more Cencora, Inc. Fundamentals Summary How do Cencora's earnings and revenue compare to its market cap? 0HF3 fundamental statistics Market cap US$43.86b Earnings (TTM ) US$1.51b Revenue (TTM ) US$293.96b
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 0HF3 income statement (TTM ) Revenue US$293.96b Cost of Revenue US$284.17b Gross Profit US$9.79b Other Expenses US$8.28b Earnings US$1.51b
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) 7.81 Gross Margin 3.33% Net Profit Margin 0.51% Debt/Equity Ratio 557.8%
How did 0HF3 perform over the long term?
See historical performance and comparison Dividends
1.0% Current Dividend Yield
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/29 16:55 End of Day Share Price 2024/12/27 00:00 Earnings 2024/09/30 Annual Earnings 2024/09/30
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Cencora, Inc. is covered by 39 analysts. 15 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution David Toung Argus Research Company Gregory Bolan Avondale Partners Eric Coldwell Baird
Show 36 more analysts 
